THE APEX TIMES
In a discussion tied to Anthropic’s IPO roadshow, Dario Amodei suggested major diseases could become “relics of the past” in under a decade. Eli Lilly’s chairman and CEO pushed back, arguing the timeline is unlikely.
Eli Lilly’s chairman and CEO Dave Ricks said he does not expect life-altering diseases to be cured on a rapid AI timeline described by Anthropic CEO Dario Amodei, according to market coverage referencing a video made for Anthropic’s IPO roadshow.
Amodei, speaking in the video, used a sweeping forecast for fields such as cancer and Alzheimer’s, characterizing them as ailments that would become “relics of the past” in less than a decade. That comment, widely circulated as companies compete to showcase the practical promise of AI in healthcare, set a high bar for how quickly new capabilities could translate into therapies.
Ricks’ response, as characterized in the coverage, was blunt: he “poured cold water” on the idea that such an outcome is likely on that schedule. While the report attributes the disagreement directly to Ricks, it does not spell out specific scientific reasons or cite particular timelines for Lilly programs in the same account.
The exchange highlights an ongoing tension in AI-linked biotech narratives. Technology leaders often discuss acceleration in drug discovery, protein design, and experimental planning, while established drug developers are constrained by biology, safety requirements, clinical trial timelines, and the long path from early research indicates to approved treatments.
For Eli Lilly, the question is not whether AI can improve parts of research and development, but how quickly those improvements can produce regulatory-grade evidence. The company operates in a sector where even for diseases with strong research foundations, approvals typically follow years of preclinical work and multiple phases of clinical testing, with additional scrutiny for durability of benefit and adverse effects.
Lilly has repeatedly emphasized that the industry’s most important bottlenecks include translating insights into validated targets and therapies that demonstrate outcomes in patients, a process AI may help but cannot compress unilaterally. Against that backdrop, Ricks’ skepticism reads as a pushback on overly optimistic public timelines for AI-driven “cures.”
Still, important details are not provided in the available coverage. It does not specify whether Ricks referenced particular Lilly pipeline assets, enrollment timelines, or trial phase durations, nor does it quantify what he considers a more realistic schedule. The report also does not include a direct, word-for-word transcript of Ricks’ remarks, beyond the characterization that he disagreed with Amodei’s “less than a decade” framing.
Investors and industry watchers will likely watch how companies temper AI optimism with measurable milestones. In the near term, the practical focus will remain on which AI-assisted approaches can show credible progress in clinical candidates, and whether leaders start aligning public expectations with the timelines required for clinical validation and regulatory review.
The investment reflects ongoing interest in obesity drug development as Pfizer expands a clinical pipeline tied to berobenatide, following its $10 billion deal for Metsera.
A recent market commentary argues that Alphabet’s Class A shares offer the best risk-adjusted “AI” exposure among the two names, while Broadcom is framed as a more return-and-volatility tradeoff.
A market update pointed to stronger revenue growth, improving volumes, ongoing brand innovation, and an upbeat 2026 outlook as reasons Coca-Cola stock pushed to a new high. The same update also cautioned that the shares trade at a premium, which can limit upside if expectations soften.
A class-action suit accuses the $3.4 trillion-asset lender of opening thousands of accounts without customer authorization over more than a decade, as plaintiffs pursue a proposed settlement.
A Yahoo Finance market note highlights that UnitedHealth (UNH) was trading about 1.9% higher roughly a month after its most recent earnings report, pointing readers to the next round of expectations for clues.
Nvidia shares slid after a report that the company’s board was preparing a leadership change, and that CEO Jensen Huang planned to step down. The shock is making Intel’s competitive position in AI compute look both more urgent and more fragile.
In remarks shared with IPO investors, Anthropic described an accelerated porting effort for its Mythos model, shrinking a task it previously said took months. The claim spotlights how quickly AI workloads can be moved across chip platforms, raising questions about how durable any compute “moat” is.
A reported shift in an analyst fair value model for Coinbase Global cut the estimate from $211.12 to $196.56, underscoring how broadly analysts’ views differ on the crypto trading platform’s outlook.
The drugmaker says it has secured the first Chinese approval for an oral, GLP-1-based treatment aimed at weight loss, marking a notable milestone for a category that has already reshaped obesity care.
In a fresh valuation note, Bank of America’s analyst lowered the 2027 outlook for Intel shares, underscoring persistent uncertainty around how the chipmaker’s strategy will translate into durable earnings power.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...